Natural bone filler solutions guaranteed to be osteoinductive to stimulate and regenerate native bone growth.
This process could provide better patient outcomes as it contains 100% allograft bone, maintaining the five key natural bone growth factors and is able to deliver these properties through malleable bone collagen in various physical forms.
Gentle soft tissue decellularisation process, removing DNA and cellular material to reduce risk of rejection.
The dCELL® process involves the creation of biological scaffolds which are essentially inert. By removing DNA and cellular material from biological tissues, the patient’s cells can repopulate and colonise, creating new, like-for-like tissue, which is recognised and accepted by the body, significantly reducing the risk of rejection, and stimulating a natural healing process.
Currently a portfolio of 12 product lines on the market which we intend to expand into further territories and have a plan for new product line developments.
Ensure that we have an innovative product pipeline, maintain product differentiation, optimise our margins and have a competitive market offering.
Building a network of key distributors and evaluating licensing opportunities for new geographic territories.
Providing a return to a better quality of life, differentiated clinical outcomes and optimised care costs.
Products with ease of use which will benefit their patients and provide economic benefits to the healthcare system.
We provide training and development opportunities, promote a positive professional culture, and support a healthy lifestyle balance.
In order to continue to create value for our stakeholders, we invest in the Group’s key resources. For example, we develop our people and our IP, as well as furthering our manufacturing capabilities.